"CONCLUSIONS
Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number,NCT01668784.)"
http://www.nejm.org/doi/full/10.1056/NEJMoa1510665
No comments:
Post a Comment